1-10 of 10
Yi Liu, PhD
Close
Sort by
Journal Articles

CRISPR/Cas9 Gene-Edited Hematopoietic Stem Cell Therapy for Sickle Cell Disease

Vionnie W. C. Yu, PhD, Yi Liu, PhD, Matthew Curran, Pu Zhang, MD, Jennifer Snead, PhD, Christian Schmedt, Yi Yang, PhD, Victor Guosheng Lin, William R Tschantz, PhD, Lisa Quinn, Carsten Russ, Scott Clarkson, Amy Janiak, Morag Stewart, PhD, Yanick Mulumba, Reynald Lescarbeau, Brad Murray, Jessica Seitzer, Walter Strapps, Hon-Ren Huang, Kevin Sloan, Craig S Mickanin, BS, Lloyd Klickstein, MD, Susan Stevenson
Journal: Blood
Blood (2017) 130 (Supplement 1): 535.
https://doi.org/10.1182/blood.V130.Suppl_1.535.535
Published: 2017
Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Steven M. Horwitz, MD, Julia J. Scarisbrick, MD FRCP, MBBS †, Reinhard Dummer, MD, Madeleine Duvic, MD, Youn H. Kim, MD, Jan Walewski, MD, Sean Whittaker, MB, ChB, FRCP, MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD, Pascal Wolter, MD, Herbert Eradat, MD, Jose A. Sanches, PhD, Pablo L. Ortiz-Romero, MD PhD, Oleg E. Akilov, MD, Judith Trotman, FRACP, Kerry Taylor, FRACP,FRCPA,MBBS, Stephane Dalle, MD PhD, Michael Weichenthal, MD, David C. Fisher, MD, Rudolf Stadler, MD, Tatyana A Feldman, MD, Timothy M. Kuzel, MD, Alejandro A. Gru, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Hui-Min Lin, PhD, Yi Liu, PhD, Meredith Little, MPH, H. Miles Prince, MD FRACP, FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 1509.
https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509
Published: 2017
Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD
Journal: Blood
Blood (2016) 128 (22): 182.
https://doi.org/10.1182/blood.V128.22.182.182
Published: 2016
Journal Articles

The NFkB System Regulates Flt3-Mediated Hematopoiesis

Yi Liu, PhD, Alexander Hoffmann, PhD
Journal: Blood
Blood (2015) 126 (23): 3592.
https://doi.org/10.1182/blood.V126.23.3592.3592
Published: 2015
Journal Articles

MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML

Zhihong Zeng, MD, Rui-Yu Wang, MD PhD, Yuexi Shi, MD, Yihua Qiu, MD, Duncan H Mak, MS, Kevin Coombes, PhD, Suk Young Yoo, PhD, Katti Jessen, Yi Liu, PhD, Christian Rommel, PhD, Hagop M. Kantarjian, MD, Steven M. Kornblau, MD, David Fruman, PhD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3613.
https://doi.org/10.1182/blood.V124.21.3613.3613
Published: 2014
Journal Articles

The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models

David A Fruman, PhD, Matthew Robert Janes, MPH, Sharmila Mallya, MS, Collin C Vu, MD, Marie P. Shieh, MD, Michael B. Lilly, MD, Leonard S Sender, MD, Michael B Martin, PhD, Pingda Ren, PhD, Yi Liu, PhD, Christian Rommel, PhD
Journal: Blood
Blood (2011) 118 (21): 2585.
https://doi.org/10.1182/blood.V118.21.2585.2585
Published: 2011
Journal Articles

Activity of the Investigational Antibody–Drug Conjugate Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large-Cell Lymphoma: Comparisons with Meta-Analyses of Historical Control Chemotherapy Data

Antonio Gualberto, MD, PhD, Andy Chi, MD, PhD, Yi Liu, PhD
Journal: Blood
Blood (2011) 118 (21): 4975.
https://doi.org/10.1182/blood.V118.21.4975.4975
Published: 2011
Journal Articles

Role of TORC1 and TORC2 in Multiple Myeloma

Patricia Maiso, PhD, Yi Liu, PhD, Abdel Kareem Azab, PhD, BSPharm, Brittany Morgan, Feda Azab, BPharm, Antonio Sacco, BS, Michaela Reagan, PhD, Hai T Ngo, BS, Yang Liu, PhD, Yong Zhang, PhD, Charles Lin, PhD, Aldo M Roccaro, MD, PhD, Christian Rommel, PhD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2011) 118 (21): 1815.
https://doi.org/10.1182/blood.V118.21.1815.1815
Published: 2011
Journal Articles

Targeting mTORC1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment

Zhihong Zeng, Yuexi Shi, Twee Tsao, Yihua Qiu, Steven M. Kornblau, MD, Keith Baggerly, Wenbin Liu, Yi Liu, PhD, Christian Rommel, PhD, David A. Fruman, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 778.
https://doi.org/10.1182/blood.V116.21.778.778
Published: 2010
Journal Articles

Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma

Patricia Maiso, PhD, AbdelKareem Azab, PhD, Yang Liu, PhD, Yong Zhang, PhD, Feda Azab, Antonio Sacco, Hai T Ngo, Yi Liu, PhD, Brittany Morgan, Christian Rommel, PhD, Kenneth C. Anderson, MD, Aldo M. Roccaro, MD, PhD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2010) 116 (21): 133.
https://doi.org/10.1182/blood.V116.21.133.133
Published: 2010